



Third Quarter 2024 Financial Results and Recent Portfolio Execution

OCTOBER 29, 2024

Agenda

Introduction | *Sanj K. Patel, Chief Executive Officer*

ARCALYST® Commercial Execution | *Ross Moat, Chief Commercial Officer*

Third Quarter 2024 Financial Results | *Mark Ragosa, Chief Financial Officer*

Closing Remarks | *Sanj K. Patel, Chief Executive Officer*

Q&A Session

Forward Looking Statements

This presentation (together with any other statements or information that we may make in connection herewith) contains forward-looking statements with respect to Kiniksa Pharmaceuticals International, plc (and its consolidated subsidiaries, collectively, unless context otherwise requires, “Kiniksa,” “we,” “us” or “our”). In some cases, you can identify forward looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “goal,” “design,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential,” “strategy,” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these identifying words. All statements contained in this presentation that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation, statements regarding our strategy; potential value drivers; potential indications; potential market opportunities and competitive position; ongoing, planned and potential clinical trials and other studies; timing and potential impact of clinical data; regulatory and other submissions, applications and approvals; commercial strategy and commercial activities; expected run rate for our cash, cash equivalents and short-term investments; expected funding of our operating plan; financial guidance; and capital allocation.

These statements involve known and unknown risks, uncertainties, and other important factors that may cause our actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements, including, without limitation: delays or difficulty in enrollment of patients in, and activation or continuation of sites for, our clinical trials; delays or difficulty in completing our clinical trials as originally designed; potential for changes between final data and any preliminary, interim, top-line or other data from clinical trials; our inability to replicate results from our earlier clinical trials or studies; impact of additional data from us or other companies, including the potential for our data to produce negative, inconclusive or commercially uncompetitive results; potential undesirable side effects caused by our products and product candidates; our inability to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities; potential for applicable regulatory authorities to not accept our filings, delay or deny approval of any of our product candidates or require additional data or trials to support approval; our reliance on third parties as the sole source of supply of the drug substance and drug product used in our products and product candidates; raw material, important ancillary product and drug substance and/or drug product shortages; our reliance on third parties to conduct research, clinical trials, and/or certain regulatory activities for our product candidates; complications in coordinating requirements, regulations and guidelines of regulatory authorities across jurisdictions for our clinical trials; changes in our operating plan, business development strategy or funding requirements; and existing or new competition.

These and the important factors discussed in our filings with the U.S. Securities and Exchange Commission, including under the caption “Risk Factors” contained therein could cause actual results to differ materially from those indicated by the forward-looking statements made in this presentation. These forward-looking statements reflect various assumptions of Kiniksa’s management that may or may not prove to be correct. No forward-looking statement is a guarantee of future results, performance, or achievements, and one should avoid placing undue reliance on such statements. Except as otherwise indicated, this presentation speaks as of the date of this presentation. We undertake no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

This presentation also contains estimates, projections, and/or other information regarding our industry, our business and the markets for certain of our product candidates, including data regarding the estimated size of those markets, and the incidence and prevalence of certain medical conditions. Unless otherwise expressly stated, we obtained this industry, business, market and other data from reports, research surveys, clinical trials, studies and similar data prepared by market research firms and other third parties, from industry, medical and general publications, and from government data and similar sources. Information that is based on estimates, forecasts, projections, market research, or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances reflected in this information.

ARCALYST is a registered trademark of Regeneron Pharmaceuticals, Inc. Kiniksa OneConnect is a trademark of Kiniksa Pharmaceuticals. All other trademarks are the property of their respective owners.





Introduction

Sanj K. Patel

Chief Executive Officer

Q3 2024 Business Highlights

Driving ARCALYST Revenue

- ✓ Q3 2024 ARCALYST revenue of **\$112.2M** representing 73% year-over-year growth
- ✓ Full-year 2024 net revenue guidance increased to **between \$410 and \$420 million** from our previous guidance of between \$405 and \$415 million



Advancing Abiprubart Development

- ✓ Continue to enroll and dose Phase 2b clinical trial of abiprubart in Sjögren's Disease
- ✓ Abiprubart clinical development in Sjögren's Disease fully funded




Maintaining Financial Strength

- ✓ Strong financial position with **\$223.8M in cash**
- ✓ Company expects to remain **cash flow positive** on an annual basis

Strong ARCALYST Growth Driven by Robust Commercial Execution

Year-Over-Year Net Revenue Growth



Key Revenue Drivers

Total Prescribers ¹	>2,550
Repeat Prescribers ¹ (% of Total)	~25%
Payer Approval ¹ (% of Completed Cases)	>90%
Average Total Duration of Therapy ¹	~27 months
Patient Compliance ¹	>85%

~11% Penetration of Multiple-Recurrence Target Population As of the End of Q2 2024



1) Data since launch through 9/30/2024




ARCALYST Commercial Execution

Ross Moat

Chief Commercial Officer

Prescriber Base Growth Accompanied by Accelerated Repeat Prescribing

Total and Repeat Prescribers of ARCALYST for Recurrent Pericarditis Patients




~45%
of new prescriptions in Q3 written by repeat prescribers

Doctors Considering ARCALYST Earlier in Patients' Disease Course


Market research suggests ~15% of prescriptions are for 1st recurrence patients; ~85% for multiple recurrence patients

% of Prescribers Considering ARCALYST by Recurrence¹
(n= 200 Cardiologists / Rheumatologists)



• Physicians are increasingly reporting consideration of ARCALYST use earlier in disease, in addition to patients with multiple recurrences

% of Prescriptions by Number of Recurrences¹



• Majority of ARCALYST prescribing continues to come from 14K target population
• ~15% of prescriptions are for patients in their 1st recurrence



1) HCP market research 2024; Kiniksa data on file

Initiatives Aimed at Advancing Disease Awareness

Proactive approach and access to expert care are critical for improving RP patient outcomes


Life DisRPted™ Campaign with National Hockey League Hall-of-Famer, Henrik Lundqvist, and GRAMMY® Award-Winning Singer-Songwriter, Carly Pearce, Aimed at Promoting Early Diagnosis and Treatment of Recurrent Pericarditis

**LIFE
DISRPTEd™**




Carly Pearce

GRAMMY® Award-Winning
Singer-Songwriter



Initiative with AHA to Improve Quality of Care through Identification, Dissemination, and Implementation of Best Practices for the Diagnosis and Management of Recurrent Pericarditis




Need for Education: 96% of patients reported that they were **incorrectly diagnosed** with other conditions prior to their recurrent pericarditis diagnosis; **average of 2.7 misdiagnoses** before their recurrent pericarditis diagnosis¹



1) Kiniksa market research

2024 ARCALYST Net Product Sales Guidance

Revenue guidance increased to \$410-\$420M from \$405-\$415M based on accelerated growth year-to-date



2021 = 9 months of availability (Q2-Q4)



Third Quarter 2024 Financials

Mark Ragosa

Chief Financial Officer

Third Quarter 2024 Financial Results

Income Statement	Three Months Ended September 30,	
	2024	2023
Product Revenue	\$112.2M	\$64.8M
License and Collaboration Revenue	\$0.0M	\$2.2M
Total Revenue	\$112.2M	\$67.0M
Cost of Goods Sold	\$20.1M	\$9.1M
Collaboration Expenses ¹	\$29.3M	\$17.3M
Research and Development	\$26.1M	\$17.1M
Selling, General and Administrative	\$46.4M	\$34.5M
Total Operating Expenses	\$121.9M	\$78.0M
Other Income	\$2.5M	\$2.4M
Income Tax Benefit (Provision)	(\$5.5M)	(\$5.4M)
Net Income (Loss)	(\$12.7M)	(\$13.9M)

Collaboration Expenses ¹	Three Months Ended September 30,	
	2024	2023
ARCALYST Net Sales	\$112.2M	\$64.8M
Profit Split-Eligible Cost of Goods Sold ²	(\$19.9M)	(\$8.8M)
Commercial, Marketing, Regulatory and Other Expenses	(\$34.1M)	(\$21.4M)
ARCALYST Collaboration Operating Profit	\$58.2M	\$34.6M
ARCALYST Collaboration Expense	\$29.1M	\$17.3M
ARCALYST Out-Licensing ³	\$0.0M	\$0.0M
ARCALYST Collaboration Expense	\$29.1M	\$17.3M
Other Collaboration Expenses	\$0.2M	\$0.0M
Total Collaboration Expenses¹	\$29.3M	\$17.3M

Balance Sheet	September 30, 2024	December 31, 2023
Cash, Cash Equivalents and Short-term Investments	\$223.8M	\$206.4M

Expect to remain cash flow positive on an annual basis



- 1) Subject to the terms of the definitive agreements between Kiniksa and Regeneron; 50% of ARCALYST Collaboration Operating Profit plus 50% of ARCALYST Licensing Proceeds;
 2) Profit Split-Eligible Cost of Goods Sold = total cost of goods sold - amortization of Regeneron milestone payment
 3) Revenue associated with ARCALYST Out-Licensing is included in Licensing and Collaboration Revenue



Closing Remarks

Sanj K. Patel

Chief Executive Officer



Third Quarter 2024 Financial Results and Recent Portfolio Execution

OCTOBER 29, 2024